Company intelligence / Profile preview
Oculogenex
La Habra, California, United Statesoculogenex.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Oculogenex is developing a novel adeno-associated viral (AAV) gene therapy for degenerative retinal diseases. Preclinical data show the approach enhances resistance to cellular stress, repairs damage, increases cell lifespan, and may activate dormant retinal stem cells. The company is preparing for Phase I clinical trials targeting dry AMD and related conditions. No active clinical trials are currently listed on ClinicalTrials.gov.
- Therapeutic areas
- Ophthalmology
- Modalities
- Gene therapy (AAV-mediated gene transfer)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Forge Biologics (AAV process development and manufacturing partnership)ISS National Laboratory/NASA collaboration for space-based research model of AMD progression
Beyond the preview
Go deeper on Oculogenex.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oculogenex.